NO972526D0 - Tachykininantagonister - Google Patents
TachykininantagonisterInfo
- Publication number
- NO972526D0 NO972526D0 NO972526A NO972526A NO972526D0 NO 972526 D0 NO972526 D0 NO 972526D0 NO 972526 A NO972526 A NO 972526A NO 972526 A NO972526 A NO 972526A NO 972526 D0 NO972526 D0 NO 972526D0
- Authority
- NO
- Norway
- Prior art keywords
- tachykinin antagonists
- tachykinin
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9425085.9A GB9425085D0 (en) | 1994-12-13 | 1994-12-13 | Organic compounds |
| GBGB9426016.3A GB9426016D0 (en) | 1994-12-22 | 1994-12-22 | Organic compounds |
| PCT/EP1995/004910 WO1996018643A1 (fr) | 1994-12-13 | 1995-12-12 | Antagonistes de la tachykinine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO972526L NO972526L (no) | 1997-06-03 |
| NO972526D0 true NO972526D0 (no) | 1997-06-03 |
Family
ID=26306161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO972526A NO972526D0 (no) | 1994-12-13 | 1997-06-03 | Tachykininantagonister |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0797583A1 (fr) |
| JP (1) | JPH10511935A (fr) |
| AR (1) | AR001332A1 (fr) |
| AU (1) | AU4343796A (fr) |
| BR (1) | BR9509997A (fr) |
| CA (1) | CA2204130A1 (fr) |
| CO (1) | CO4700289A1 (fr) |
| CZ (1) | CZ179097A3 (fr) |
| FI (1) | FI971685A (fr) |
| HU (1) | HUT77002A (fr) |
| IL (1) | IL116323A0 (fr) |
| NO (1) | NO972526D0 (fr) |
| PE (1) | PE38997A1 (fr) |
| PL (1) | PL320217A1 (fr) |
| SK (1) | SK74697A3 (fr) |
| TR (1) | TR199501568A2 (fr) |
| WO (1) | WO1996018643A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| CA2266773A1 (fr) * | 1996-10-07 | 1998-04-16 | Merck Sharp & Dohme Limited | Utilisation de l'antagoniste du recepteur nk-1 utilise comme antidepresseur et/ou agent anxiolytique |
| CN1157224C (zh) | 1999-02-18 | 2004-07-14 | 科研制药株式会社 | 用作生长激素促分泌剂的新酰胺衍生物 |
| NZ552397A (en) | 2004-07-15 | 2011-04-29 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| WO2006123182A2 (fr) | 2005-05-17 | 2006-11-23 | Merck Sharp & Dohme Limited | Sulfones de cyclohexyle pour le traitement du cancer |
| KR20080044840A (ko) | 2005-07-15 | 2008-05-21 | 에이엠알 테크놀로지, 인크. | 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 용도 |
| EP1940842B1 (fr) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4 |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| JP5489333B2 (ja) | 2006-09-22 | 2014-05-14 | メルク・シャープ・アンド・ドーム・コーポレーション | 脂肪酸合成阻害剤を用いた治療の方法 |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| PL2336120T3 (pl) | 2007-01-10 | 2014-12-31 | Msd Italia Srl | Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP) |
| US8093268B2 (en) | 2007-01-24 | 2012-01-10 | Glaxo Group Limited | Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-) |
| EP2145884B1 (fr) | 2007-04-02 | 2014-08-06 | Msd K.K. | Dérivé d'indoledione |
| AU2008269154B2 (en) | 2007-06-27 | 2014-06-12 | Merck Sharp & Dohme Llc | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| JP2011515343A (ja) | 2008-03-03 | 2011-05-19 | タイガー ファーマテック | チロシンキナーゼ阻害薬 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| WO2010132442A1 (fr) | 2009-05-12 | 2010-11-18 | Albany Molecular Reserch, Inc. | 7-([1,2, 4,]triazolo[1,5,-a]pyridine-6-yl)-4-(3,4-dichlorophényl)-1,2,3,4- tétrahydroisoquinoline et son utilisation |
| EP2429295B1 (fr) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryle, hétéroaryle et tétrahydroisoquinolines à hétérocycle substitué et leur utilisation |
| EP2429293B1 (fr) | 2009-05-12 | 2014-10-29 | Bristol-Myers Squibb Company | FORMES CRISTALLINES DE (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN -6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE ET LEURS UTILISATIONS |
| WO2011046771A1 (fr) | 2009-10-14 | 2011-04-21 | Schering Corporation | Pipéridines substituées qui accroissent l'activité de p53, et utilisations de ces composés |
| WO2011163330A1 (fr) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk |
| CA2805265A1 (fr) | 2010-08-02 | 2012-02-09 | Merck Sharp & Dohme Corp. | Inhibition a mediation par interference arn de catenine (proteine associee a cadherine), expression du gene beta 1 (ctnnb1) a l'aide de petit acide nucleique interferent (sian) |
| CA2807307C (fr) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Inhibition mediee par des arn interferents de l'expression genique du virus de l'hepatite b (vhb) a l'aide de petits acides nucleiques interferents (pani) |
| EP2608669B1 (fr) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor |
| WO2012030685A2 (fr) | 2010-09-01 | 2012-03-08 | Schering Corporation | Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk |
| EP2615916B1 (fr) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk |
| ES2663009T3 (es) | 2010-10-29 | 2018-04-10 | Sirna Therapeutics, Inc. | Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic) |
| EP2654748B1 (fr) | 2010-12-21 | 2016-07-27 | Merck Sharp & Dohme Corp. | Dérivés d'indazole utiles en tant qu'inhibiteurs de erk |
| JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子１受容体阻害剤 |
| US9023865B2 (en) | 2011-10-27 | 2015-05-05 | Merck Sharp & Dohme Corp. | Compounds that are ERK inhibitors |
| EP3358013B1 (fr) | 2012-05-02 | 2020-06-24 | Sirna Therapeutics, Inc. | Compositions d'acide nucléique interférent court (sina) |
| JP6280554B2 (ja) | 2012-09-28 | 2018-02-14 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｅｒｋ阻害剤である新規化合物 |
| BR112015012295A8 (pt) | 2012-11-28 | 2023-03-14 | Merck Sharp & Dohme | Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer |
| MX2015008196A (es) | 2012-12-20 | 2015-09-16 | Merck Sharp & Dohme | Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana. |
| WO2014120748A1 (fr) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2 |
| EP3041938A1 (fr) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Polynucléotides circulaires |
| WO2018071283A1 (fr) | 2016-10-12 | 2018-04-19 | Merck Sharp & Dohme Corp. | Inhibiteurs de kdm5 |
| WO2019094311A1 (fr) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| EP3706747A4 (fr) | 2017-11-08 | 2021-08-04 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| EP3833668A4 (fr) | 2018-08-07 | 2022-05-11 | Merck Sharp & Dohme Corp. | Inhibiteurs de prmt5 |
| EP3833667B1 (fr) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Inhibiteurs de prmt5 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5164372A (en) * | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH05186498A (ja) * | 1991-12-27 | 1993-07-27 | Japan Tobacco Inc | プロリン誘導体 |
-
1995
- 1995-12-11 PE PE1995286859A patent/PE38997A1/es not_active Application Discontinuation
- 1995-12-11 IL IL11632395A patent/IL116323A0/xx unknown
- 1995-12-12 SK SK746-97A patent/SK74697A3/sk unknown
- 1995-12-12 JP JP8518261A patent/JPH10511935A/ja active Pending
- 1995-12-12 CZ CZ971790A patent/CZ179097A3/cs unknown
- 1995-12-12 CO CO95058767A patent/CO4700289A1/es unknown
- 1995-12-12 PL PL95320217A patent/PL320217A1/xx unknown
- 1995-12-12 HU HU9701897A patent/HUT77002A/hu unknown
- 1995-12-12 AU AU43437/96A patent/AU4343796A/en not_active Abandoned
- 1995-12-12 EP EP95942131A patent/EP0797583A1/fr not_active Withdrawn
- 1995-12-12 BR BR9509997A patent/BR9509997A/pt not_active Application Discontinuation
- 1995-12-12 WO PCT/EP1995/004910 patent/WO1996018643A1/fr not_active Application Discontinuation
- 1995-12-12 CA CA002204130A patent/CA2204130A1/fr not_active Abandoned
- 1995-12-13 AR AR33458995A patent/AR001332A1/es unknown
- 1995-12-13 TR TR95/01568A patent/TR199501568A2/xx unknown
-
1997
- 1997-04-18 FI FI971685A patent/FI971685A/fi not_active Application Discontinuation
- 1997-06-03 NO NO972526A patent/NO972526D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2204130A1 (fr) | 1996-06-20 |
| JPH10511935A (ja) | 1998-11-17 |
| AR001332A1 (es) | 1997-10-22 |
| FI971685A0 (fi) | 1997-04-18 |
| PE38997A1 (es) | 1997-10-02 |
| EP0797583A1 (fr) | 1997-10-01 |
| IL116323A0 (en) | 1996-03-31 |
| NO972526L (no) | 1997-06-03 |
| FI971685A (fi) | 1997-08-13 |
| CZ179097A3 (en) | 1997-10-15 |
| AU4343796A (en) | 1996-07-03 |
| CO4700289A1 (es) | 1998-12-29 |
| HUT77002A (hu) | 1998-03-02 |
| SK74697A3 (en) | 1997-11-05 |
| WO1996018643A1 (fr) | 1996-06-20 |
| BR9509997A (pt) | 1997-12-30 |
| PL320217A1 (en) | 1997-09-15 |
| MX9703957A (es) | 1997-09-30 |
| TR199501568A2 (tr) | 1996-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI971685A (fi) | Takykiniini-antagonisteja | |
| EE9600186A (et) | Neurokiniini (tahhüülkiniini) antagonistid | |
| NO951613D0 (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
| DK0738150T3 (da) | Bicykliske fibrinogene antagonister | |
| DE69719354D1 (de) | Muscarin-antagonisten | |
| FI955927A0 (fi) | Substituoidut 1H-imidatsolit | |
| PT805813E (pt) | Antagonistas de vasopressina triciclicos | |
| DE69534718D1 (de) | Substituierte 9-alkyladenine | |
| DK0824098T3 (da) | 4-Hydroxy-piperidinderivater | |
| DE69511456D1 (de) | Pfostenanordnung | |
| ATE232526T1 (de) | 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten | |
| DE69732715D1 (de) | Tachykinin antagoniste | |
| NO179550C (no) | Tachykinin reseptorantagonister | |
| DE69735811D1 (de) | Piperazinoderivate als neurokinin-antagonisten | |
| NO975541D0 (no) | 4-hydroksy-piperidinderivater | |
| BR9509559A (pt) | Azolilulsolfonilfeniluracilas substituídas | |
| FI965116A0 (fi) | Uusia opioidipeptidiantagonisteja | |
| BR9506770A (pt) | Cicloaminas substituídas com tiofeno | |
| KR950031851U (ko) | 다슬기 포획기 | |
| KR970702876A (ko) | 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists) | |
| KR950027351U (ko) | 반목 항타장치 | |
| DK0964867T3 (da) | Tachykininantagonister | |
| DE59510274D1 (de) | Substituierte biphenyloxazoline | |
| KR980000737U (ko) | 수세미 | |
| DE59503458D1 (de) | Balkon |